

# Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2020

<https://marketpublishers.com/r/G7529725ECBEN.html>

Date: September 2020

Pages: 770

Price: US\$ 2,000.00 (Single User License)

ID: G7529725ECBEN

## Abstracts

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease - Pipeline Review, H2 2020, provides an overview of the Graft Versus Host Disease (Immunology) pipeline landscape.

Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, and diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment includes immunosuppressants.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graft Versus Host Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graft Versus Host Disease (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by

Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 12, 38, 15, 3, 39, 8 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 13 and 1 molecules, respectively. Graft Versus Host Disease (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:**

Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

**SCOPE**

The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (Immunology).

The pipeline guide reviews pipeline therapeutics for Graft Versus Host Disease (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Graft Versus Host Disease (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Graft Versus Host Disease (Immunology)

therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (Immunology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Graft Versus Host Disease (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Graft Versus Host Disease (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## Contents

Introduction

Graft Versus Host Disease (GVHD) - Overview

Graft Versus Host Disease (GVHD) - Therapeutics Development

Graft Versus Host Disease (GVHD) - Therapeutics Assessment

Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development

Graft Versus Host Disease (GVHD) - Drug Profiles

Graft Versus Host Disease (GVHD) - Dormant Projects

Graft Versus Host Disease (GVHD) - Discontinued Products

Graft Versus Host Disease (GVHD) - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc, H2 2020

Graft Versus Host Disease (GVHD) - Pipeline by Adienne Pharma & Biotech, H2 2020

Graft Versus Host Disease (GVHD) - Pipeline by AltruBio Inc, H2 2020

Graft Versus Host Disease (GVHD) - Pipeline by Amgen Inc, H2 2020

Graft Versus Host Disease (GVHD) - Pipeline by AnaptysBio Inc, H2 2020

Graft Versus Host Disease (GVHD) - Pipeline by apceth Biopharma GmbH, H2 2020

Graft Versus Host Disease (GVHD) - Pipeline by ASC Therapeutics Inc, H2 2020

Graft Versus Host Disease (GVHD) - Pipeline by AstraZeneca Plc, H2 2020

Graft Versus Host Disease (GVHD) - Pipeline by Athersys Inc, H2 2020

Graft Versus Host Disease (GVHD) - Pipeline by Autolus Therapeutics Plc, H2 2020

Graft Versus Host Disease (GVHD) - Dormant Projects, H2 2020

Graft Versus Host Disease (GVHD) - Discontinued Products, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

### COMPANIES MENTIONED

AbbVie Inc

Adienne Pharma & Biotech

AltruBio Inc

Amgen Inc

AnaptysBio Inc

apceth Biopharma GmbH

ASC Therapeutics Inc

AstraZeneca Plc

Athersys Inc

Autolus Therapeutics Plc

Bellicum Pharmaceuticals Inc

Biocon Ltd

Biogen Inc

BioIncept LLC

BioTheryX Inc

BlueRock Therapeutics

Boryung ViGenCell Inc

Bristol-Myers Squibb Co

Capricor Therapeutics Inc

Cellect Biotechnology Ltd

Collective BioTherapy Inc  
Cellix Bio Pvt Ltd  
CheckPoint Immunology Inc  
Clinigen Group Plc  
CSL Ltd  
CTI BioPharma Corp  
Cytodyn Inc  
Cytpeutics Pte Ltd  
Daewoong Pharmaceutical Co Ltd  
Dualogics Corp  
Educell doo  
Eli Lilly and Co  
enGene Inc  
Enlivex Therapeutics Ltd  
Evive Biotech  
ExCellThera Inc  
F. Hoffmann-La Roche Ltd  
Fate Therapeutics Inc  
Fujifilm Holdings Corp  
Genentech USA Inc  
GigaGen Inc  
GlaxoSmithKline Plc  
Glia LLC  
Humanigen Inc  
iCELL Biotechnology Co Ltd  
Implacate  
Immune Modulation Inc  
ImmuneTarget Inc  
Imstem Biotechnology Inc  
Incyte Corp  
Inspyr Therapeutics Inc  
Jazz Pharmaceuticals Plc  
JN Biosciences LLC  
Kadmon Corp LLC  
Kalytera Therapeutics Inc  
Kamada Ltd  
Kiniksa Pharmaceuticals Ltd  
Kymab Ltd  
LG Chem Ltd



MaaT Pharma  
Machavert Pharmaceuticals LLC  
Magenta Therapeutics Inc  
Mallinckrodt Plc  
Medexus Pharmaceuticals Inc  
Medicenna Therapeutics Corp  
Mediolanum farmaceutici SpA  
Medsenic SAS  
Mereo Biopharma Group Plc  
Mesoblast Ltd  
Millennium Pharmaceuticals Inc  
MitoImmune Therapeutics Inc  
NapaJen Pharma Inc  
Neovii Pharmaceuticals AG  
Nurix Therapeutics Inc  
OncolImmune Inc  
OSE Immunotherapeutics  
Panorama Research Inc  
Pfizer Inc  
Platinum Biotech (Beijing) Co Ltd  
Pluristem Therapeutics Inc  
Precision Biosciences Inc  
REGiMMUNE Corp  
SCM lifescience Co Ltd  
Seattle Genetics Inc  
Secura Bio Inc  
Seres Therapeutics Inc  
Shenzhen Chipscreen Biosciences Co Ltd  
STERO Biotechs Ltd  
StingInn LLC  
Suzhou Connect Biopharmaceuticals Ltd  
Suzhou Zelgen Biopharmaceutical Co Ltd  
Syndax Pharmaceuticals Inc  
Synthetic Biologics Inc  
Takeda Pharmaceutical Co Ltd  
Targazyme Inc  
TCF GmbH  
TeralImmune Inc  
TGV Laboratories Inc

United BioPharma Inc

Vault Pharma Inc

Visterra Inc

Xenikos BV

Xenothera SAS

XL-protein GmbH

## I would like to order

Product name: Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/G7529725ECBEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7529725ECBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970